NFL Biosciences SAS (ALNFL) - Net Assets
Based on the latest financial reports, NFL Biosciences SAS (ALNFL) has net assets worth €1.82 Million EUR (≈ $2.13 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.42 Million ≈ $5.17 Million USD) and total liabilities (€2.60 Million ≈ $3.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NFL Biosciences SAS liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.82 Million |
| % of Total Assets | 41.16% |
| Annual Growth Rate | 52.66% |
| 5-Year Change | 550.84% |
| 10-Year Change | N/A |
| Growth Volatility | 770.13 |
NFL Biosciences SAS - Net Assets Trend (2018–2024)
This chart illustrates how NFL Biosciences SAS's net assets have evolved over time, based on quarterly financial data. Also explore total assets of NFL Biosciences SAS for the complete picture of this company's asset base.
Annual Net Assets for NFL Biosciences SAS (2018–2024)
The table below shows the annual net assets of NFL Biosciences SAS from 2018 to 2024. For live valuation and market cap data, see market cap of NFL Biosciences SAS.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €976.43K ≈ $1.14 Million |
+179.02% |
| 2023-12-31 | €349.94K ≈ $409.12K |
-58.54% |
| 2022-12-31 | €844.00K ≈ $986.72K |
-74.33% |
| 2021-12-31 | €3.29 Million ≈ $3.84 Million |
+2091.29% |
| 2020-12-31 | €150.03K ≈ $175.39K |
-63.54% |
| 2019-12-31 | €411.52K ≈ $481.12K |
+433.81% |
| 2018-12-31 | €77.09K ≈ $90.13K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NFL Biosciences SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 198392800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €294.91K | 30.20% |
| Other Components | €2.76 Million | 282.90% |
| Total Equity | €976.43K | 100.00% |
NFL Biosciences SAS Competitors by Market Cap
The table below lists competitors of NFL Biosciences SAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MRO-TEK Realty Limited
NSE:MRO-TEK
|
$14.48 Million |
|
Relpol SA
WAR:RLP
|
$14.49 Million |
|
Excel Realty N Infra Limited
NSE:EXCEL
|
$14.49 Million |
|
Icandy Interactive Ltd
AU:ICI
|
$14.50 Million |
|
Sampann Utpadan India Limited
NSE:SAMPANN
|
$14.46 Million |
|
Australian Vintage Ltd
AU:AVG
|
$14.45 Million |
|
Photomyne Ltd
TA:PHTM
|
$14.45 Million |
|
City Chic Collective Ltd
AU:CCX
|
$14.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NFL Biosciences SAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 349,945 to 976,430, a change of 626,485 (179.0%).
- Net loss of 2,080,839 reduced equity.
- Other factors increased equity by 2,707,324.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.08 Million | -213.11% |
| Other Changes | €2.71 Million | +277.27% |
| Total Change | €- | 179.02% |
Book Value vs Market Value Analysis
This analysis compares NFL Biosciences SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 67.90x to 10.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.01 | €1.00 | x |
| 2019-12-31 | €0.08 | €1.00 | x |
| 2020-12-31 | €0.03 | €1.00 | x |
| 2021-12-31 | €0.63 | €1.00 | x |
| 2022-12-31 | €0.16 | €1.00 | x |
| 2023-12-31 | €0.04 | €1.00 | x |
| 2024-12-31 | €0.10 | €1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NFL Biosciences SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -213.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4523563.04%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.70x
- Recent ROE (-213.11%) is above the historical average (-307.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -65.11% | 0.00% | 0.00x | 1.13x | €-309.11K |
| 2020 | -177.63% | -8882866.67% | 0.00x | 3.84x | €-281.49K |
| 2021 | -29.76% | -2508317.95% | 0.00x | 1.12x | €-1.31 Million |
| 2022 | -289.51% | 0.00% | 0.00x | 2.84x | €-2.53 Million |
| 2023 | -1070.30% | -1872.64% | 0.05x | 11.35x | €-3.78 Million |
| 2024 | -213.11% | -4523563.04% | 0.00x | 3.70x | €-2.18 Million |
Industry Comparison
This section compares NFL Biosciences SAS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,878,829
- Average return on equity (ROE) among peers: -55.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NFL Biosciences SAS (ALNFL) | €1.82 Million | -65.11% | 1.43x | $14.47 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $123.48 Million |
| Abivax SA (ABVX) | $71.74 Million | -22.24% | 0.06x | $6.97 Billion |
| Adocia (ADOC) | $-12.97 Million | 0.00% | 0.00x | $107.15 Million |
| Aelis Farma SA (AELIS) | $19.79 Million | -72.20% | 0.98x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $7.01 Million | -199.64% | 2.12x | $875.93K |
| Cellectis (ALCLS) | $9.11 Million | 0.00% | 0.47x | $268.18 Million |
| Advicenne (ALDVI) | $-19.07 Million | 0.00% | 0.00x | $20.93 Million |
| Genoway (ALGEN) | $5.10 Million | 5.12% | 0.91x | $30.11 Million |
| Integragen (ALINT) | $1.28 Million | -213.59% | 2.27x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.08 Million | 0.00% | 0.00x | $1.80 Million |
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more